Drugs / EP0062
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05573126 | Jan 2023 → Feb 2028 expected | hormone receptor-positive breast cancer | Ellipses Pharma | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EP0062 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05573126 ↗ |
| Modality | Other / unclassified | “selective androgen receptor modulator (SARM)” NCT05573126 ↗ |
| Route | Oral | “orally administered” NCT05573126 ↗ |